Organism, minimum inhibitory concentration, and outcome in a fungal corneal ulcer clinical trial

Cornea

Volumn 31, Issue 6, 2012, Pages 662-667

  Lalitha, Prajna ^a   Prajna, N Venkatesh ^a   Oldenburg, Catherine E ^b   Srinivasan, Muthiah ^a   Krishnan, Tiruvengada ^a   Mascarenhas, Jeena ^a   Vaitilingam, C M ^a   McLeod, Stephen D ^b,c   Zegans, Michael E ^d,e   Porco, Travis C ^b,c   Acharya, Nisha R ^b,c   Lietman, Thomas M ^b,c  

^a ARAVIND EYE CARE SYSTEM   (India)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^e DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

fungus; keratitis, susceptibility, voriconazole, natamycin

Indexed keywords

FLUCONAZOLE; NATAMYCIN; VORICONAZOLE;

ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; ASPERGILLUS; BEST SPECTACLE CORRECTED VISUAL ACUITY; CORNEA EPITHELIUM; CORNEA PERFORATION; CORNEA REEPITHELIALIZATION; CORNEA SCAR SIZE; EPITHELIZATION; FUNGUS ISOLATION; FUSARIUM; HUMAN; KERATOMYCOSIS; MAJOR CLINICAL STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; SCAR FORMATION; TISSUE REGENERATION; TREATMENT OUTCOME; VISUAL ACUITY;

ANTIFUNGAL AGENTS; CORNEAL ULCER; DOUBLE-BLIND METHOD; EYE INFECTIONS, FUNGAL; FUNGI; HUMANS; MICROBIAL SENSITIVITY TESTS; MYCOSES; NATAMYCIN; PROSPECTIVE STUDIES; PYRIMIDINES; TREATMENT OUTCOME; TRIAZOLES; VISUAL ACUITY;

EID: 84861094890     PISSN: 02773740     EISSN: 15364798     Source Type: Journal    
DOI: 10.1097/ICO.0b013e31823f8ae0     Document Type: Article

References (28)

1. Whitcher JP, Srinivasan M, Upadhyay MP. Corneal blindness: a global perspective. Bull World Health Organ. 2001;79:214-221.
2. Chowdhary A, Singh K. Spectrum of fungal keratitis in North India. Cornea. 2005;24:8-15.
3. Laspina F, Samudio M, Cibils D, et al. Epidemiological characteristics of microbiological results on patients with infectious corneal ulcers: a 13-year survey in Paraguay. Graefes Arch Clin Exp Ophthalmol. 2004;242:204-209.
4. Leck A, Thomas PA, Hagan M, et al. Aetiology of suppurative corneal ulcers in Ghana and South India, and epidemiology of fungal keratitis. Br J Ophthalmol. 2002;86:1211-1215.
5. Srinivasan M, Gonzales CA, George C, et al. Epidemiology and aetiological diagnosis of corneal ulceration in Madurai, South India. Br J Ophthalmol. 1997;81:965-971.
6. Srinivasan M. Fungal keratitis. Curr Opin Ophthalmol. 2004;15:321-327.
7. Chen A, Prajna L, Srinivasan M, et al. Does in vitro susceptibility predict clinical outcome in bacterial keratitis? Am J Ophthalmol. 2008;145:409-412.
8. Shapiro BL, Lalitha P, Loh AR, et al. Susceptibility testing and clinical outcome in fungal keratitis. Br J Ophthalmol. 2010;94:384-385.
9. Wilhelmus KR, Abshire RL, Schlech BA. Influence of fluoroquinolone susceptibility on the therapeutic response of fluoroquinolone-treated bacterial keratitis. Arch Ophthalmol. 2003;121:1229-1233.
10. Lalitha P, Shapiro BL, Srinivasan M, et al. Antimicrobial susceptibility of Fusarium, Aspergillus, and other filamentous fungi isolated from keratitis. Arch Ophthalmol. 2007;125:789-793.
11. Marangon FB, Miller D, Giaconi JA, et al. In vitro investigation of voriconazole susceptibility for keratitis and endophthalmitis fungal pathogens. Am J Ophthalmol. 2004;137:820-825.
12. Prajna NV, Mascarenhas J, Krishnan T, et al. Comparison of natamycin and voriconazole for the treatment of fungal keratitis. Arch Ophthalmol. 2010;128:672-678.
13. Larone D. Medically Important Fungi: A Guide to Identification. 4th ed. Washington, DC: ASM Press; 2002.
14. NCCLS. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Filamentous Fungi: Approved Standard NCCLS document M38-A 2. Wayne, PA: Clinical and Laboratory Standards Institute; 2002.
15. Iyer S, Tuli SS, Wagoner RC. Fungal keratitis: emerging trends and treatment outcomes. Eye Contact Lens. 2006;32:267-271.
16. Jurkunas U, Behlau I, Colby K. Fungal keratitis: changing pathogens and risk factors. Cornea. 2009;28:638-643.
17. Galarreta DJ, Tuft SJ, Ramsay A, et al. Fungal keratitis in London: microbiological and clinical evaluation. Cornea. 2007;26:1082-1086.
18. Green M, Apel A, Stapleton F. A longitudinal study of trends in keratitis in Australia. Cornea. 2008;27:33-39.
19. Ritterband DC, Seedor JA, Shah MK, et al. Fungal keratitis at the New York Eye and Ear Infirmary. Cornea. 2006;25:264-267.
20. Xie L, Zhong W, Shi W, et al. Spectrum of fungal keratitis in north China. Ophthalmology. 2006;113:1943-1948.
21. Lalitha P, Prajna NV, Kabra A, et al. Risk factors for treatment outcome in fungal keratitis. Ophthalmology. 2006;113:526-530.
22. Lau D, Fedinands M, Leung L, et al. Penetration of voriconazole, 1%, eyedrops into human aqueous humor: a prospective open-label study. Arch Ophthalmol. 2008;126:343-346.
23. O'Day DM, Head WS, Robinson RD, et al. Corneal penetration of topical amphotericin B and natamycin. Curr Eye Res. 1986;5:877-882.
24. Thiel MA, Zinkernagel AS, Burhenne J, et al. Voriconazole concentration in human aqueous humor and plasma during topical or combined topical and systemic administration for fungal keratitis. Antimicrob Agents Chemother. 2007;51:239-244.
25. Rex JH, Pfaller MA. Has antifungal susceptibility testing come of age? Clin Infect Dis. 2002;35:982-989.
26. Weinstein MP, Reller LB, Murphy JR, et al. The clinical significance of positive blood cultures: a comprehensive analysis of 500 episodes of bacteremia and fungemia in adults. I. Laboratory and epidemiologic observations. Rev of Infect Dis. 1983;5:35-53.
27. Lass-Florl C, Kofler G, Kropshofer G, et al. In-vitro testing of susceptibility to amphotericin B is a reliable predictor of clinical outcome in invasive aspergillosis. J Antimicrob Chemother. 1998;42:497-502.
28. Vemulakonda GA, Hariparasad SM, Mieler WF, et al. Aqueous and vitreous concentrations following topical administration of 1% voriconazole in humans. Arch Ophthalmol. 2008;126:18-22.